Feng Chi Biotech (ROCO:6744) Change In Receivables: NT$1.2 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6744 Feng Chi Biotech Corp ROCO:6744
82 GF Score
Price NT$15.50
GF Value NT$18.03
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Feng Chi Biotech Change In Receivables?

Feng Chi Biotech ROCO:6744 +5.08% 82 Change In Receivables is NT$1.2 Mil as of Jun. 2026. GuruFocus rates ROCO:6744 with a GF Score™ of 82/100 and a GF Value™ of NT$18.03 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Feng Chi Biotech's change in receivables for the quarter that ended in Jun. 2026 was NT$-5.5 Mil. It means Feng Chi Biotech's Accounts Receivable increased by NT$5.5 Mil from Dec. 2025 to Jun. 2026 .

Feng Chi Biotech's change in receivables for the fiscal year that ended in Dec. 2025 was NT$0.6 Mil. It means Feng Chi Biotech's Accounts Receivable declined by NT$0.6 Mil from Dec. 2024 to Dec. 2025 .

Feng Chi Biotech's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$20.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Feng Chi Biotech's Days Sales Outstanding for the six months ended in Jun. 2026 was 49.71.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Feng Chi Biotech's liquidation value for the six months ended in Jun. 2026 was NT$151.0 Mil.

Feng Chi Biotech  (ROCO:6744) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Feng Chi Biotech's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=20.611/75.668*91
=49.71

2. In Ben Graham's calculation of liquidation value, Feng Chi Biotech's accounts receivable are only considered to be worth 75% of book value:

Feng Chi Biotech's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=171.849-51.618+0.75 * 20.611+0.5 * 30.533
=151.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech Change In Receivables Related Terms

Feng Chi Biotech Change In Receivables Historical Data

* Premium members only.

The historical data trend for Feng Chi Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech Change In Receivables Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 1.07 -3.38 -1.01 0.59

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 0.27 -6.10 6.69 -5.50
ROCO:6744
82GF Score
Feng Chi Biotech Corp ROCO:6744
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Feng Chi Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$1.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$1.2 Mil mean?
Feng Chi Biotech (ROCO:6744) has a Change In Receivables of NT$1.2 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Feng Chi Biotech and its competitors.
Is Feng Chi Biotech's Change In Receivables too high?
Feng Chi Biotech's current Change In Receivables is NT$1.2 Mil. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's Change In Receivables compare to VRTX and REGN?
Feng Chi Biotech's Change In Receivables of NT$1.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Feng Chi Biotech and its competitors. Feng Chi Biotech's current Change In Receivables is NT$1.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$18.03, compared to a current price of NT$15.50 — trading 14% below its estimated fair value. The current Change In Receivables is NT$1.2 Mil. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current Change In Receivables is NT$1.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?

Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued. The current stock price of NT$15.50 is trading 14% below its estimated GF Value™ of NT$18.03. GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.

Key valuation signals for ROCO:6744:

  • Change In Receivables: NT$1.2 Mil
  • GF Value™: NT$18.03 vs. price of NT$15.50 (14% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Feng Chi Biotech Business Description

Address No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score

Get the complete analysis for ROCO:6744

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.50
Price
NT$18.03
GF Value